Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more

PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II... read more

Key Highlights: 92% complete response (CR) rate: Eleven of twelve evaluable patients achieved a centrally confirmed pathologic CR following a... read more

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to... read more

Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place,... read more

Privo Technologies (Privo), a Massachusetts-based company with roots in the Langer lab at MIT, has been selected to introduce its... read more

The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more

Privo Technologies, Inc., a clinical-stage biopharmaceutical company pioneering nanotechnology-based cancer therapies, is thrilled to announce the activation of multiple premier... read more